Denosumab Biosimilar(Prestige BioPharma)

地舒单抗生物类似药(Prestige BioPharma)

Report date: 2024/02/01 17:47:30

Base Information

Drug NameDenosumab Biosimilar(Prestige BioPharma)
Drug Alias NamePBP1601PBP-1601
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsEndocrine System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPrestige BioPharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPrestige BioPharma Ltd
Inactive CompaniesN/A
Active IndicationsEndocrine System Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A